Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Budd-Chiari syndrome diagnosis marker

A syndrome and diagnostic cloth technology, applied in the field of disease diagnosis, can solve the problems of poor natural prognosis, lag in research, lack of effective methods for early diagnosis and treatment, and achieve the effect of providing survival rate

Active Publication Date: 2017-02-22
北京微未来科技有限公司
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] BCS can cause liver damage, portal hypertension, and even serious complications such as liver cirrhosis, liver failure, and upper gastrointestinal bleeding.
The early clinical manifestations of BCS patients are hidden and non-specific, and there is no effective method for early diagnosis and treatment. Most of the patients are in the late stage when they see a doctor, and the clinical manifestations are complex and diverse, which is easy to cause misdiagnosis and mistreatment.
Domestic research on BCS is mostly focused on clinical treatment, compared with epidemiological and etiological research lagging behind, lack of national census and etiological research

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Budd-Chiari syndrome diagnosis marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Example 1 Screening of differentially expressed genes

[0039] 1. Research objects and sample collection

[0040] (1) Research objects: 3 patients with Budd-Chiari syndrome and 5 normal volunteers.

[0041] (2) Sample collection: The subjects were required to fast for at least 12 hours, and at room temperature from 7:00 to 8:00 in the morning of the next day, 10ml of venous blood was drawn into ethylenediaminetetraacetic acid (EDTA) anticoagulant tubes, and 3 times the volume of red blood cells was added for lysis. solution, mix well, place at room temperature for 10 minutes, and centrifuge at 10,000 rpm for 1 minute. Discard the supernatant thoroughly and collect the white blood cell pellet. Add 1ml TRIzol to every 100-200μl blood collected white blood cell pellet, and freeze it at -80℃ for later use.

[0042] 2. Acquisition of total RNA

[0043] Total RNA in blood leukocytes was extracted using TRIzol according to conventional methods.

[0044] 3. RNA concentrati...

Embodiment 2

[0057] Example 2 Large sample verification screened out differentially expressed genes

[0058] The SNCA gene was selected for validation.

[0059] 1. Sample collection

[0060] According to the method in Example 1, 50 peripheral blood samples were collected from Budd-Chiari syndrome patients and 50 normal people.

[0061] 2. Validation at the mRNA level

[0062] 2.1 Extraction of total RNA from blood

[0063] Step is with embodiment 1.

[0064] 2.2 Reverse transcription

[0065] Reverse transcription using Primescript 1 st strand cDNA synthesis kit kit, the operation steps are as follows:

[0066] (1) Add the following reaction liquid in the microcentrifuge tube, as shown in Table 1:

[0067] Table 1 Reaction liquid

[0068] Reagent dose RNA 2.0μg dNTP 1.0μl Oligo(dT) 2.0μl RNase free dH 2 o

Add to 10.0μl

[0069] (2) Incubate at 70°C for 5 minutes, then rapidly cool to 4°C;

[0070] Add the following reagents into a ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses Budd-Chiari syndrome diagnosis marker-SNCA (Alpha-synuclein) gene; by detecting SNCA gene expression product content in blood of a subject, it is possible to judge whether the subject suffers from Budd-Chiari syndrome, or diagnose whether the subject has the risk of suffering from Budd-Chiari syndrome, or judge whether subject experiences recurrence or judge prognosis conditions of the subject. Based on research results of the invention, the invention also discloses a kit for diagnosing Budd-Chiari syndrome, the kit is suitable for the diagnosis of early Budd-Chiari syndrome and is easy to popularize and use clinically.

Description

technical field [0001] The invention relates to the field of disease diagnosis, more specifically, the invention relates to the application of SNCA in the diagnosis of Budd-Chiari syndrome. Background technique [0002] Budd-Chiari syndrome (BCS) is a posthepatic portal syndrome characterized by obstructive lesions of the inferior vena cava above the hepatic vein and / or its opening, often accompanied by inferior vena cava syndrome. hypertension. From a global perspective, the incidence of BCS is low, and its etiology has obvious regional differences. In western countries, BCS with hepatic vein obstruction is more common, and most of them have clear etiologies, such as oral contraceptives, pregnancy, and blood diseases. It has been reported in the literature that hepatic venous BCS is related to blood hypercoagulability and hepatic vein thrombosis caused by gene mutations; while in Asia and South Africa, IVC obstructive BCS is more common, and the etiology is mostly unclear....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68G01N33/68
Inventor 杨承刚任静宋宏涛
Owner 北京微未来科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com